# A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)

> **NCT03263715** · PHASE3 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 39 (actual)

## Conditions studied

- Polymyalgia Rheumatica

## Interventions

- **DRUG:** Tocilizumab Prefilled Syringe [Actemra]
- **DRUG:** Placebos
- **DRUG:** Glucocorticoids

## Key facts

- **NCT ID:** NCT03263715
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-24
- **Primary completion:** 2020-06-02
- **Final completion:** 2020-06-02
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2021-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03263715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03263715, "A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03263715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*